SOUTH SAN FRANCISCO, Calif., May 22 /PRNewswire-FirstCall/ -- Corgentech Inc. will host a webcast conference call on Wednesday, May 24, 2006 at 4:30 p.m. Eastern Time. Members of Corgentech’s management team plan to provide additional detail about the commercial opportunity for its lead pain management product candidates: 3268, a fast-acting topical local anesthetic for which the company plans to submit a New Drug Application with the U.S. Food and Drug Administration in the summer, and 4975, a novel, long-acting, non-opioid for treating moderate-to-severe pain.
Interested parties can listen to the live audio webcast and view the accompanying slide presentation, or the subsequent archived recording, by logging on to www.corgentech.com and going to the Investor Information page. Please connect to Corgentech’s website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary. For those unable to participate via the Internet, a 24-hour replay will be available for seven days after the call by calling 1(800) 642-1687, or (706) 645-9291 for international callers, and giving the following pass code: 9649306.
About Corgentech
Corgentech is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has four drug candidates in clinical development for multiple potential indications, the most advanced of which, 3268, has completed Phase 3 clinical trials. To reflect the company’s core focus on novel pain management therapies, the board of directors recently voted to change the company name to Anesiva. If approved by stockholders at the annual meeting on June 21, 2006, the name change will become effective immediately thereafter. Corgentech is based in South San Francisco, CA.
Forward Looking Statements
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. Forward- looking statements in this press release include, without limitation, projected timing of FDA filings and clinical data announcements and other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: whether Corgentech can successfully develop new products and the degree to which these gain market acceptance. Actual results may differ materially from those contained in the forward- looking statements in this press release. Additional information concerning these and other risk factors is contained in Corgentech’s quarterly report on Form 10-Q for the quarter ended March 31, 2006.
Corgentech undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.
Corgentech Inc.
CONTACT: Richard Powers, Chief Financial Officer of Corgentech Inc.,+1-650-624-9600, or investors@corgentech.com; or Daryl Messinger, Media ofWeissComm Partners, +1-415-999-2361, or daryl@weisscommpartners.com, forCorgentech Inc.
Web site: http://www.corgentech.com//
